+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Brain & Spinal Cord Cancer Market by Cancer Type, Treatment Type, Patient Age Group, End User, Distribution Channel - Global Forecast to 2030- Product Image
Brain & Spinal Cord Cancer Market by Cancer Type, Treatment Type, Patient Age Group, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Brain & Spinal Cord Cancer Market by Cancer Type, Treatment Type, Patient Age Group, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968082
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Brain & Spinal Cord Cancer Market grew from USD 3.98 billion in 2024 to USD 4.21 billion in 2025. It is expected to continue growing at a CAGR of 5.82%, reaching USD 5.59 billion by 2030.

Setting the Stage for Breakthroughs in Neuro-Oncology

Brain and spinal cord cancer poses one of the most formidable challenges in contemporary oncology, characterized by complex pathophysiology, diverse histological subtypes, and persistently high unmet clinical needs. As incidence rates continue to edge upward in many regions, driven in part by aging populations and improvements in diagnostic imaging, stakeholders across the healthcare ecosystem must grapple with escalating demands for innovative therapies and advanced diagnostic modalities. Survival outcomes remain relatively poor for aggressive subtypes such as glioblastoma, while rarer entities like ependymoma and oligodendroglioma present their own unique therapeutic hurdles.

This executive summary synthesizes the critical trends shaping the market for brain and spinal cord cancer therapeutics and care. Drawing upon rigorous data collection, proprietary analysis, and expert perspectives, it offers a clear view of shifts in clinical practice, emerging treatment modalities, and the economic forces influencing access and affordability. By framing the landscape through the lenses of regulatory developments, competitive dynamics, and patient-centric considerations, this overview sets the stage for strategic decision-making among manufacturers, payers, clinicians, and investors.

Revolutionary Shifts Reshaping Brain and Spinal Cord Cancer Care

The last two years have witnessed revolutionary advances that are redefining standards of care in neuro-oncology. Genomic profiling has transitioned from research settings into routine diagnostics, enabling precision targeting of molecular drivers in subtypes such as astrocytoma and meningioma. Oncolytic viruses and checkpoint inhibitors have secured regulatory milestones, while emerging CAR T cell therapies are entering pivotal trials for glioblastoma. Simultaneously, innovative surgical techniques-ranging from laser interstitial thermal ablation to minimally invasive resection-are minimizing neurological deficits and accelerating postoperative recovery.

Beyond therapeutic innovations, breakthroughs in imaging technologies and artificial intelligence-driven radiomics are refining tumor characterization and treatment planning. Adaptive radiation platforms, including stereotactic systems and proton therapy, offer enhanced dose conformity that spares healthy tissue. These paradigm shifts underscore a broader move toward integrated care pathways that leverage multimodal regimens, digital health tools, and patient-reported outcome measures, ensuring that treatment adapts dynamically to individual disease trajectories.

Navigating the New Trade Landscape Impacting Treatment Access

The introduction of U.S. tariffs on select medical equipment, diagnostics, and pharmacological imports in early 2025 has reshaped cost structures across the neuro-oncology sector. Tariffs applied to advanced imaging hardware have driven up acquisition costs for key technologies, prompting hospitals and ambulatory centers to reassess capital budgets and procurement strategies. Pharmaceutical tariffs affecting active pharmaceutical ingredients have exerted upward pressure on treatment expenditures, with downstream impacts on payer negotiations and patient out-of-pocket liabilities.

Manufacturers have responded by optimizing supply chain footprints, onshoring production of critical reagents, and negotiating volume-based agreements to mitigate price inflation. Clinical trial budgets have absorbed a portion of these incremental costs, potentially affecting the pace of late-stage programs. As a result, stakeholders are forecasting shifts in deployment timelines for novel modalities and reexamining market entry strategies. Close collaboration among regulatory bodies, industry consortia, and health systems will be essential to preserve access while balancing fiscal sustainability.

Granular Perspectives from Multi-Dimensional Market Segments

A nuanced segmentation framework provides deeper clarity on demand drivers and inefficiencies within the brain and spinal cord cancer domain. When dissecting cancer types, seven distinct histologies emerge-from aggressive glioblastoma to typically benign meningioma-each presenting divergent incidence rates, survival curves, and therapeutic protocols. Treatment modalities span a spectrum that includes established regimens such as alkylating agents alongside next-generation nitrosoureas and platinum complexes, all the way to cutting-edge approaches like CAR T cell therapy and immune checkpoint blockade. Radiation options diversify further into traditional external beam systems, highly conformal proton delivery, and stereotactic radiosurgery, while surgical intervention ranges from open craniotomy to laser ablation and other minimally invasive resections. Supportive care remains integral for symptom management and quality-of-life preservation, and targeted therapies-specifically kinase inhibitors and monoclonal antibodies-are forging pathways to personalized regimens.

Population stratification by age highlights distinct epidemiological and therapeutic considerations for adult, geriatric, and pediatric cohorts, with pediatric medulloblastoma protocols often demanding specialized supportive frameworks. End-user environments span from high-throughput hospitals and dedicated cancer clinics to ambulatory surgical centers and home-care settings, each requiring tailored service models and reimbursement pathways. Finally, distribution channels covering clinic pharmacies, hospital dispensaries, online storefronts, retail outlets, and specialty stores reveal diverse access points for medications and consumables, shaping logistical strategies and patient engagement initiatives.

Diverse Regional Dynamics Driving Global Market Evolution

Regional intricacies play a pivotal role in shaping the global market for brain and spinal cord cancer interventions. In the Americas, the combination of advanced reimbursement frameworks, robust R&D investment, and centralized regulatory pathways in the United States has historically set the pace for innovation, while key Latin American markets are gradually expanding diagnostic networks and clinical program participation. Europe benefits from harmonized standards under the European Medicines Agency, although national health technology assessment processes introduce variability in adoption timelines across individual countries. In Middle Eastern and African territories, growing public-private partnerships and philanthropic initiatives are enhancing oncology infrastructure, yet financial constraints and workforce shortages continue to pose barriers.

Asia-Pacific markets display heterogenous dynamics: mature markets such as Japan and Australia demonstrate rapid uptake of proton therapy and targeted agents, whereas emerging economies in Southeast Asia and India are balancing affordability with access, often through tiered pricing agreements and localized manufacturing collaborations. Collectively, these regional dynamics underscore the importance of adaptive market entry strategies and differentiated value propositions tailored to local regulatory, economic, and clinical landscapes.

Competitive Landscape and Strategic Priorities of Leading Innovators

The competitive arena features a blend of pharmaceutical titans and specialized device innovators. Global leaders have fortified pipelines with next-generation alkylating compounds and bispecific antibodies, while strategic acquisitions have bolstered portfolios in immuno-oncology and neuro-surgical technologies. Device manufacturers are enhancing platforms for laser ablation and stereotactic radiosurgery through software upgrades and integrated imaging, aiming to improve intraoperative guidance and patient outcomes.

Collaboration agreements between biotech firms and academic centers are accelerating early-stage research, especially in biomarkers and cell therapy vectors. Partnerships with contract research organizations are optimizing clinical trial execution across multiple regions, ensuring geographic diversity and expedited enrollment. Meanwhile, regional players are focusing on cost-effective diagnostics and generic formulations to capture underserved markets. As the race intensifies, the ability to demonstrate real-world evidence and navigate evolving pricing environments will determine long-term market share.

Strategic Imperatives for Advancing Treatment and Market Position

Developing a resilient and forward-looking strategy requires a multifaceted approach. Industry leaders should prioritize investment in biomarker-driven R&D to accelerate personalized treatments and enhance regulatory success rates. Strengthening digital health integrations, such as remote monitoring and tele-oncology platforms, can drive patient adherence and reduce disparities in access.

Supply chain diversification will mitigate exposure to tariff-related cost spikes and logistical disruptions, while local manufacturing partnerships can secure critical inventory buffers. Engaging proactively with payers and health authorities to establish value-based pricing agreements will be essential in aligning reimbursement with clinical outcomes. Additionally, fostering cross-sector alliances with academic institutions, patient advocacy groups, and technology vendors will catalyze innovation and reinforce credibility. By embedding real-world evidence collection into pivotal trials and post-launch studies, organizations can substantiate health economic value and accelerate market uptake.

Robust Methodological Framework Underpinning Market Insights

This analysis is anchored in a rigorous, multi-tiered research methodology designed to ensure validity and reliability. Secondary data sources encompass peer-reviewed journals, governmental databases, industry white papers, and patent registries, providing a comprehensive backdrop of clinical and commercial intelligence. Primary research involved structured interviews with oncologists, neurosurgeons, hospital pharmacists, payers, and patient advocates, delivering firsthand insights on treatment paradigms and access challenges.

Quantitative surveys among healthcare providers and end-user facilities yielded granular data on utilization patterns and procurement strategies. Market sizing and share were triangulated through the integration of supplier shipment records, public financial disclosures, and proprietary analytics. The research framework was further bolstered by expert advisory panels who validated assumptions, interpreted emerging trends, and identified critical inflection points within the brain and spinal cord cancer landscape.

Synthesizing Insights to Chart the Path Forward

This executive summary has articulated the intricate dynamics of brain and spinal cord cancer care, from histological diversity and treatment innovations to tariff-driven cost pressures and regional complexities. It has illuminated segmentation strategies that reveal unmet needs across patient populations and end-user environments, while competitive analysis underscores the strategic maneuvers of leading stakeholders. The research has also highlighted actionable recommendations that can guide R&D pipelines, operational resilience, and market access initiatives. By synthesizing data across multiple dimensions, this overview equips decision-makers with the clarity needed to navigate a rapidly evolving landscape and to capitalize on opportunities that promise improved patient outcomes and sustainable growth.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Cancer Type
    • Astrocytoma
    • Ependymoma
    • Glioblastoma
    • Medulloblastoma
    • Meningioma
    • Oligodendroglioma
    • Schwannoma
  • Treatment Type
    • Chemotherapy
      • Alkylating Agents
      • Nitrosoureas
      • Platinum Based Agents
    • Immunotherapy
      • CAR T Cell Therapy
      • Checkpoint Inhibitors
    • Radiation Therapy
      • External Beam Radiation
      • Proton Therapy
      • Stereotactic Radiosurgery
    • Supportive Care
    • Surgery
      • Craniotomy
      • Laser Ablation
      • Minimally Invasive Resection
    • Targeted Therapy
      • Kinase Inhibitors
      • Monoclonal Antibodies
  • Patient Age Group
    • Adult
    • Geriatric
    • Pediatric
  • End User
    • Ambulatory Surgical Centers
    • Cancer Clinics
    • Home Care Settings
    • Hospitals
  • Distribution Channel
    • Clinic Pharmacies
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
    • Specialty Stores
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • AbbVie Inc.
  • Bayer AG
  • Novocure Limited
  • Eisai Co., Ltd.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Brain & Spinal Cord Cancer Market, by Cancer Type
8.1. Introduction
8.2. Astrocytoma
8.3. Ependymoma
8.4. Glioblastoma
8.5. Medulloblastoma
8.6. Meningioma
8.7. Oligodendroglioma
8.8. Schwannoma
9. Brain & Spinal Cord Cancer Market, by Treatment Type
9.1. Introduction
9.2. Chemotherapy
9.2.1. Alkylating Agents
9.2.2. Nitrosoureas
9.2.3. Platinum Based Agents
9.3. Immunotherapy
9.3.1. CAR T Cell Therapy
9.3.2. Checkpoint Inhibitors
9.4. Radiation Therapy
9.4.1. External Beam Radiation
9.4.2. Proton Therapy
9.4.3. Stereotactic Radiosurgery
9.5. Supportive Care
9.6. Surgery
9.6.1. Craniotomy
9.6.2. Laser Ablation
9.6.3. Minimally Invasive Resection
9.7. Targeted Therapy
9.7.1. Kinase Inhibitors
9.7.2. Monoclonal Antibodies
10. Brain & Spinal Cord Cancer Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Brain & Spinal Cord Cancer Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Cancer Clinics
11.4. Home Care Settings
11.5. Hospitals
12. Brain & Spinal Cord Cancer Market, by Distribution Channel
12.1. Introduction
12.2. Clinic Pharmacies
12.3. Hospital Pharmacies
12.4. Online Pharmacies
12.5. Retail Pharmacies
12.6. Specialty Stores
13. Americas Brain & Spinal Cord Cancer Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Brain & Spinal Cord Cancer Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Brain & Spinal Cord Cancer Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. F. Hoffmann-La Roche Ltd
16.3.3. Pfizer Inc.
16.3.4. Merck & Co., Inc.
16.3.5. Bristol-Myers Squibb Company
16.3.6. AstraZeneca PLC
16.3.7. AbbVie Inc.
16.3.8. Bayer AG
16.3.9. Novocure Limited
16.3.10. Eisai Co., Ltd.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. BRAIN & SPINAL CORD CANCER MARKET MULTI-CURRENCY
FIGURE 2. BRAIN & SPINAL CORD CANCER MARKET MULTI-LANGUAGE
FIGURE 3. BRAIN & SPINAL CORD CANCER MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BRAIN & SPINAL CORD CANCER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BRAIN & SPINAL CORD CANCER MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BRAIN & SPINAL CORD CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ASTROCYTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EPENDYMOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SCHWANNOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY NITROSOUREAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PLATINUM BASED AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY EXTERNAL BEAM RADIATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PROTON THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STEREOTACTIC RADIOSURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CRANIOTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY LASER ABLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MINIMALLY INVASIVE RESECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CLINIC PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SPECIALTY STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 76. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 77. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 78. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 80. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 81. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 82. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 83. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 84. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. CANADA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 87. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 89. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 90. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 91. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 92. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 93. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 94. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. MEXICO BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 138. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 139. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 140. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 141. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 142. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 143. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 144. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. GERMANY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 150. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 151. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 152. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 153. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 154. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 155. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. FRANCE BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 168. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 170. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 171. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 172. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 173. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 174. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 175. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. ITALY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 177. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 178. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 179. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 180. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 181. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 182. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 183. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 184. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 185. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. SPAIN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 212. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 213. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 218. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 220. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 222. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 223. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 224. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. DENMARK BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 238. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 239. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 240. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 241. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 242. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 243. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 244. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 245. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. QATAR BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 248. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 251. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 252. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 253. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 254. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 255. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. FINLAND BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 262. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 263. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 264. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 271. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 272. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 273. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 274. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 275. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. NIGERIA BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 277. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 278. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 280. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 281. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 282. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 283. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 284. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. EGYPT BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 288. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 289. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 290. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 291. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 292. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 293. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 294. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 295. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 296. TURKEY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 307. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 308. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 309. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 310. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 311. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY RADIATION THERAPY, 2018-2030 (USD MILLION)
TABLE 312. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
TABLE 313. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 314. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 315. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 316. NORWAY BRAIN & SPINAL CORD CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILL

Companies Mentioned

The companies profiled in this Brain & Spinal Cord Cancer market report include:
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • AbbVie Inc.
  • Bayer AG
  • Novocure Limited
  • Eisai Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages180
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.21 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.59 Billion
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Spinal Cord Neurostimulation Implant Market by Product Type, Technology, Electrode Type, Application, End User, Stimulation Approach, Distribution Channel - Global Forecast to 2030 - Product Image

Spinal Cord Neurostimulation Implant Market by Product Type, Technology, Electrode Type, Application, End User, Stimulation Approach, Distribution Channel - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Spinal Cord Trauma Treatment - Global Strategic Business Report - Product Image

Spinal Cord Trauma Treatment - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Acute Spinal Cord Injury Market Report 2025 - Product Image

Acute Spinal Cord Injury Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Spinal Cord Stimulator Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Spinal Cord Stimulator Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 95 Pages
  • Global
From
Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172 - Product Image

Nanowired Delivery of Drugs and Antibodies for Neuroprotection in Brain Diseases with Co-Morbidity Factors Part B. International Review of Neurobiology Volume 172

  • Book
  • Global
Copyright © 2002-2025 Research and Markets. All Rights Reserved.